Incelldx didn’t conduct occupancy tests on the mono trial patients until the last cohort. This was not completed on all the patients in the trial. From my understanding, the data is available and perfect. So, for NP to claim that Incelldx’s occupancy test is somehow to blame for the delay in the HIV BLA is false. The efficacy data alone supports approval and doesn’t require occupancy data to support that approval. Additionally, as others have pointed out, NP and Amarex never mentioned the occupancy test as one of the reasons the HIV BLA received the RTF during the CC after the RTF was received. This is July a recent claim that NP is making.